SHPH Shuttle Pharmaceuticals
- 0.440
- +0.010+2.33%
- 0.440
- 0.0000.00%
Shuttle Pharmaceuticals News
Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
GAITHERSBURG, Md., April 23, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Shuttle Pharmaceuticals Files to Sell Subscription Rights to Buy $4.5M in Units
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
12 Health Care Stocks Moving In Friday's After-Market Session
GainersSalarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The market value of their outstanding shares is at $3.2 million. Masimo (NASDAQ:MASI) sha
Shuttle Pharmaceuticals Q4 EPS $(0.11) Down From $(0.06) YoY
Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(0.11) per share. This is a 83.33 percent decrease over losses of $(0.06) per share from the same period last year.
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused...
Shuttle Pharmaceuticals Has Been Granted European Patent Number EP3737376 Titled "Selective Histone Deacetylase Inhibitors For The Treatment Of Human Diseases (Including Cancers, Neurological Disorders, And Immunological Disorders)"
Shuttle Pharmaceuticals Has Been Granted European Patent Number EP3737376 Titled "Selective Histone Deacetylase Inhibitors For The Treatment Of Human Diseases (Including Cancers, Neurological Disorder
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024
Webcast presentation to take place at 11:25am ETROCKVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty
Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now
Shuttle Pharmaceuticals to Launch $4.5 Million Rights Offering
Shuttle Pharmaceuticals Advances Prostate Cancer Diagnostics Funding
Shuttle Pharmaceuticals Bolsters Investor Relations With New Partnership
Shuttle Pharmaceuticals Acquires Promising Prostate Cancer Technology
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the...
12 Health Care Stocks Moving In Monday's Intraday Session
GainersSagimet Biosciences (NASDAQ:SGMT) stock rose 103.5% to $13.88 during Monday's regular session. The company's market cap stands at $317.8 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares moved up
12 Health Care Stocks Moving In Friday's Intraday Session
GainersEdgewise Therapeutics (NASDAQ:EWTX) stock moved upwards by 35.8% to $13.15 during Friday's regular session. The market value of their outstanding shares is at $834.8 million. Bullfrog AI Hldgs
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersAssure Hldgs (NASDAQ:IONM) stock moved upwards by 13.3% to $0.31 during Thursday's after-market session. The company's market cap stands at $2.0 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) s
Shuttle Pharmaceuticals Receives FDA Approval to Proceed With Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced they have received the 'Safe to Proceed' letter from the U.S....
Analysis
Price Target
No Data
